title: PHARMAC and the statin debacle.
abstract: Statins are lipid-modifying drugs which dramatically lower the total and low-density lipoprotein cholesterol levels and have been shown in large clinical trials to reduce the rate of vascular events, including heart attacks, strokes, and death. For every 1% reduction in the LDL cholesterol level, the relative risk for major coronary heart disease events is reduced by approximately 1%. Since the landmark Scandinavian Simvastatin Survival Study (4S) was published in 1994, multiple further clinical trials have reinforced the benefits of treating large numbers of patients with statins with the emphasis on achieving low LDL cholesterol levels (currently 1.6 mmol/L) for the optimal management of patients at very high risk. However PHARMAC's actions since statins were first available have significantly impaired the optimal management of New Zealand patients. A review of the methods employed during the statin era is a useful exercise in understanding how PHARMAC functions and emphasises the point that rather than achieving low-cost prices for drugs, PHARMAC simply impedes the timely delivery of modern medicines to New Zealand patients.
authors.affiliation: Greenlane Cardiovascular Service, Auckland City Hospital, Auckland. chrise@adhb.govt.nz
authors.forename: Chris
authors.initials: C
authors.lastname: Ellis
authors.forename: Harvey
authors.initials: H
authors.lastname: White
mesh_terms: D004341:Drug Evaluation; D004335:Drug and Narcotic Control; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000191:economics* / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000188:drug therapy* / Q000191:economics*; D007356:Insurance, Pharmaceutical Services; D009313:National Health Programs; D009520:New Zealand
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors